Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.

By J. Ong, A. Pitts, Z. Younossi. Journal of Hepatology, 2008

637 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/f61652eba297d82101c5c2612fdb1835420fda06

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Z. Younossi
2. S. Bellentani
3. C. Day
4. Y. Sumida
5. M. Yoneda
6. V. Ratziu
7. H. Cortez‐Pinto
8. A. Baranova

In Hepatology

1. Y. Sumida
2. M. Yoneda
3. S. Bellentani
4. C. Day
5. Z. Younossi

In Pathology and Forensic Medicine

1. Z. Younossi
2. S. Bellentani
3. A. Baranova
4. C. Day
5. G. Vernon

Citations in the corpus

• Current and future pharmacological therapies for NAFLD/NASH (2017, background): “However, the leading cause of mortality in patients with NAFLD is cardiovascular diseases, followed by extrahepatic cancer and liver-related diseases [105].”
• Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults (2011, background): “In the era of genomics medicine, it is important to mention recent evidence connecting genotyping data to the epidemiology of NAFLD.”
• A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, background): “Long-term follow-up studies have shown that NASH increases overall mortality by 35–85% compared to the age and sex-matched general population [51,70,71].”
• Epidemiology of Non-Alcoholic Fatty Liver Disease (2010, positive): “requires the presence of central obesity (waist circumference >94 cm for European men and >80 cm for European women) and at least two of the following factors: (1) triglycerides >1.70 mmol/l or specific treatment, (2) HDL-cholesterol 130 mm Hg or diastolic >85 mm Hg or specific treatment, and/or (4”